Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Jun. 16, 2023	Jan. 20, 2017	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 16, 2022
Options
Outstanding balance at the beginning of the period (in shares)			1,191,715	852,266
Granted (in shares)			2,393,500	402,490
Forfeited (in shares)			(200,849)	(63,041)
Outstanding balance at the end of the period (in shares)			3,384,366	1,191,715	852,266
Options exercisable at the end of the period (in shares)			1,382,078
Options vested and expected to vest at end of period (in shares)			3,384,366
Weighted Average Exercise Price Per Share
Outstanding balance at the beginning of the period (in dollars per share)			$ 35.94	$ 44.76
Granted (in dollars per share)			2.67	15.03
Forfeited (in dollars per share)			9.73	21.65
Outstanding balance at the end of the period (in dollars per share)			13.97	$ 35.94	$ 44.76
Options exercisable at the end of the period (in dollars per share)			28.80
Options vested and expected to vest at end of the period (in dollars per share)			$ 13.97
Weighted Average Remaining Life in Years
Outstanding balance			8 years 4 months 24 days	7 years 5 months 19 days	7 years 6 months 29 days
Options exercisable at end of period			6 years 10 months 13 days
Options vested and expected to vest at end of the period			8 years 4 months 24 days
Aggregate Intrinsic Value
Outstanding balance			$ 3,431	$ 7,673	$ 7,670
Options vested and expected to vest at end of the period			$ 3,431
Assumptions used to determine grant-date fair value
Expected volatility			90.44%	82.70%
Weighted average risk-free interest rate			4.05%	3.10%
Expected dividend yield			0.00%	0.00%
Expected term (in years)			6 years 5 months 26 days	6 years 5 months 1 day
Expiration period			10 years
Unrecognized compensation cost related to non-vested stock options			$ 5,444
Minimum
Assumptions used to determine grant-date fair value
Vesting period			3 years
Maximum
Assumptions used to determine grant-date fair value
Vesting period			4 years
Weighted Average [Member]
Assumptions used to determine grant-date fair value
Weighted average period for recognition of compensation cost			2 years 2 months 8 days
2016 Plan
Assumptions used to determine grant-date fair value
Annual increase in authorized shares (as a percent)		4.00%
Number of options or stock awards available for grant under the Plan			1,016,023
2022 Plan
Assumptions used to determine grant-date fair value
Number of options or stock awards available for grant under the Plan						750,000
Additional shares approved for future issuance	2,250,000
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Stock Based Compensation Expense			$ 5,128	$ 5,180
Options to purchase common stock | Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Stock Based Compensation Expense			2,647	2,540
Options to purchase common stock | General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Stock Based Compensation Expense			2,481	$ 2,640
Restricted stock units to purchase common stock
Assumptions used to determine grant-date fair value
Vested			5,242
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Unrecognized compensation costs related to RSUs granted to employees			$ 1,682
Restricted stock units to purchase common stock | Executive Officer
Assumptions used to determine grant-date fair value
Vesting period			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Awarded				265,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Stock Based Compensation Expense			$ 1,632	$ 2,086
Restricted stock units to purchase common stock | 2016 Plan
Options
Forfeited (in shares)			(30,000)
Weighted Average Exercise Price Per Share
Forfeited (in dollars per share)			$ 19.40
Assumptions used to determine grant-date fair value
Options unvested at end of period (in dollars per share)			$ 19.97	$ 18.90	$ 17.60
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at the beginning			358,560	93,560
Vested (in shares)			(66,060)
Awarded				265,000
Outstanding at the end			262,500	358,560	93,560
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Outstanding at beginning( in dollars per share)			$ 18.90	$ 17.60
Vested(in dollars per share)			14.20
Awarded				19.40
Outstanding at end(in dollars per share)			$ 19.97	$ 18.90	$ 17.60